REG - Oxford Biomedica PLC - Grant of Awards
Wed 17:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260408:nRSH7055Za&default-theme=true
RNS Number : 7055Z Oxford Biomedica PLC 08 April 2026
OXB
Grant of Awards
Oxford, UK - 08 April 2026: OXB (LSE: OXB) (the "Company"), a quality and
innovation-led cell and gene therapy CDMO, announces that on 07 April 2026,
nil-cost share options over ordinary shares of 50 pence each in the Company
were granted under the Company's 2024 Long Term Incentive Plan ("LTIP"),
including Restricted Share Units ("RSU") and the Company's 2024 Deferred Bonus
Plan ("DBP").
As detailed in the recently published 2025 Directors' Remuneration Report:-
Re-instated LTIP awards: the LTIP grants in respect of 2024 and 2025, detailed
below, reinstate the originally intended grant level for Dr. Frank Mathias and
Dr. Lucinda Crabtree's 2024 and 2025 LTIP awards. The 2024 and 2025 LTIP
awards were scaled back, primarily to manage the headroom available under the
OXB share plans. The re-instatement honors the terms on which Dr. Mathias and
Dr. Crabtree were recruited and reflects the Company's performance detailed in
the 2025 Annual report and accounts. The re-instated LTIP awards remain
subject to the original performance conditions and post-vesting holding
periods, ensuring that the vesting of the awards is subject to the sustained
strong performance of the business.
LTIP - Grant in respect of 2026: The 2026 LTIP metrics are 60% revenue, 40%
Operating EBITDA margin, with target ranges in each case assessed on a
constant currency basis which is set out in the Company's Directors'
Remuneration Report for 2025.
Type Name of individual Title Number of share options granted
LTIP - Grant in respect of 2026 Dr. Frank Mathias Chief Executive Officer 478,119
LTIP - Grant in respect of 2025 46,195
LTIP - Grant in respect of 2024 43,790
2026 DBP Dr. Frank Mathias Chief Executive Officer 71,891
LTIP - Grant in respect of 2026
156,884
Dr. Lucinda Crabtree Chief Financial Officer
LTIP - Grant in respect of 2025
26,526
LTIP - Grant in respect of 2024
12,876
2026 DBP Dr. Lucinda Crabtree Chief Financial Officer 47,179
LTIP - Grant in respect of 2026 Natalie Walter Chief Legal Officer and Group Company Secretary 75,479
2026 DBP Natalie Walter Chief Legal Officer and Group Company Secretary 12,459
LTIP - Grant in respect of 2026 Dr. Kyriacos Mitrophanous Chief Innovation Officer 72,391
2026 DBP Dr. Kyriacos Mitrophanous Chief Innovation Officer 10,841
LTIP - Grant in respect of 2026 Lisa Doman Chief People Officer 69,992
2026 DBP Lisa Doman Chief People Officer 10,629
LTIP - Grant in respect of 2026
Dr. Sébastien Ribault Chief Business Officer 107,102
2026 DBP Dr. Sébastien Ribault Chief Business Officer 14,908
LTIP - Grant in respect of 2026
Mark Caswell Site Head, UK Operations 49,431
2026 LTIP RSU Dr. Sabine Sydow Chief of Staff 7,036
2026 LTIP RSU Dr. Melanie Kearney Global Head of Quality 12,711
2026 LTIP RSU John Foy Site Head, Durham Operations 12,380
2026 LTIP RSU Stéphanie Colloud Site Head and General Manager of France Operations 10,357
2026 LTIP RSU Kathleen Miller Head of Human Resources (and acting Interim Site Head, Bedford) 12,628
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Frank Mathias
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP grant in respect of 2026 Nil 478,119
LTIP grant in respect of 2025 Nil 46,195
LTIP grant in respect of 2024 Nil 43,790
h) Aggregated information
- Aggregated volume LTIP awards granted over 478,119 shares in total
- Price Nil
LTIP awards over 46,195 shares in total
- Aggregated volume
- Nil
- Price LTIP awards over 43,790 shares in total
Nil
- Aggregated volume
- Price
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 478,119 shares in total
- Price
- Aggregated volume
-
- Price
- Aggregated volume
- Price
Nil
LTIP awards over 46,195 shares in total
Nil
LTIP awards over 43,790 shares in total
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Frank Mathias
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus
Plan. No consideration was paid for the grant of the award.
g) Price(s) and volumes(s)
Award Price Volume
DBP grant in respect of 2026 Nil 71,891
h) Aggregated information
- Aggregated volume DBP awards granted over 71,891 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
DBP awards granted over 71,891 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Lucinda Crabtree
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP grant in respect of 2026 Nil 156,884
LTIP grant in respect of 2025 Nil 26,526
LTIP grant in respect of 2024 Nil 12,876
h) Aggregated information
- Aggregated volume LTIP awards granted over 156,884 shares in total
- Price Nil
LTIP awards over 26,526 shares in total
- Aggregated volume
- Nil
- Price
LTIP awards over 12,876 shares in total
- Aggregated volume Nil
- Price
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 156,884 shares in total
- Price
- Aggregated volume
-
- Price
- Aggregated volume
- Price
Nil
LTIP awards over 26,526 shares in total
Nil
LTIP awards over 12,876 shares in total
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Lucinda Crabtree
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus
Plan. No consideration was paid for the grant of the award.
g) Price(s) and volumes(s)
Award Price Volume
DBP grant in respect of 2026 Nil 47,179
h) Aggregated information
- Aggregated volume DBP awards granted over 47,179 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
DBP awards granted over 47,179 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief Legal Officer and Group Company Secretary
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Natalie Walter
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP grant in respect of 2026 Nil 75,479
h) Aggregated information
- Aggregated volume LTIP awards granted over 75,479 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 75,479 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief Legal Officer and Group Company Secretary
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Natalie Walter
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus
Plan. No consideration was paid for the grant of the award.
g) Price(s) and volumes(s)
Award Price Volume
DBP grant in respect of 2026 Nil 12,459
h) Aggregated information
- Aggregated volume DBP awards granted over 12,459 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
DBP awards granted over 12,459 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief Business Officer
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Sébastien Ribault
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP grant in respect of 2026 Nil 107,102
h) Aggregated information
- Aggregated volume LTIP awards granted over 107,102 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 107,102 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief Business Officer
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Sébastien Ribault
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus
Plan. No consideration was paid for the grant of the award.
g) Price(s) and volumes(s)
Award Price Volume
DBP grant in respect of 2026 Nil 14,908
h) Aggregated information
- Aggregated volume DBP awards granted over 14,908 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
DBP awards granted over 14,908 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief People Officer
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Lisa Doman
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP grant in respect of 2026 Nil 69,992
h) Aggregated information
- Aggregated volume LTIP awards granted over 69,992 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 69,992 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief People Officer
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Lisa Doman
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus
Plan. No consideration was paid for the grant of the award.
g) Price(s) and volumes(s)
Award Price Volume
DBP grant in respect of 2026 Nil 10,629
h) Aggregated information
- Aggregated volume DBP awards granted over 10,629 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
DBP awards granted over 10,629 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief Innovation Officer
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Kyriacos Mitrophanous
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP grant in respect of 2026 Nil 72,391
h) Aggregated information
- Aggregated volume LTIP awards granted over 72,391 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 72,391 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief Innovation Officer
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Kyriacos Mitrophanous
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus
Plan. No consideration was paid for the grant of the award.
g) Price(s) and volumes(s)
Award Price Volume
DBP grant in respect of 2026 Nil 10,841
h) Aggregated information
- Aggregated volume DBP awards granted over 10,841 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
DBP awards granted over 10,841 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Site Head, UK Operations
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Mark Caswell
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP grant in respect of 2026 Nil 49,431
h) Aggregated information
- Aggregated volume LTIP awards granted over 49,431 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 49,431 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Chief of Staff
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Sabine Sydow
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP RSU grant in respect of 2026 Nil 7,036
h) Aggregated information
- Aggregated volume LTIP RSU awards granted over 7,036 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
LTIP RSU awards granted over 7,036 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Global Head of Quality
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Melanie Kearney
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP RSU grant in respect of 2026 Nil 12,711
h) Aggregated information
- Aggregated volume LTIP RSU awards granted over 12,711 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
LTIP RSU awards granted over 12,711 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Site Head, Durham Operations
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person John Foy
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP RSU grant in respect of 2026 Nil 12,380
h) Aggregated information
- Aggregated volume LTIP RSU awards granted over 12,380 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
LTIP RSU awards granted over 12,380 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Site Head and General Manager of France Operations
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Stephanie Colloud
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP RSU grant in respect of 2026 Nil 10,357
h) Aggregated information
- Aggregated volume LTIP RSU awards granted over 10,357 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
LTIP RSU awards granted over 10,357 shares in total
- Price
Nil
1. Details of the Issuer or emission allowance market participant
a) Full name of the entity Oxford Biomedica plc
b) LEI code 213800S1GVQNXQ15K851
2. Reason for the notification
a) Position/status Head of Human Resources (and acting Interim Site Head, Bedford)
b) Initial notification / amendment Initial Notification
3. Details of the person discharging managerial responsibilities / person closely
associated
a) Is this a PDMR or PCA Submission Submission for PDMR
b) Name of natural person Kathleen Miller
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Date of the transaction 2026-04-07
b) Description of instrument Share
c) Identification code ISIN: GB00BDFBVT43
d) Place of the transaction Outside the trading venue
e) Currency GBP - British Pound
f) Nature of the transaction Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term
Incentive Plan. No consideration was paid for the grant of the awards.
g) Price(s) and volumes(s)
Award Price Volume
LTIP RSU grant in respect of 2026 Nil 12,628
h) Aggregated information
- Aggregated volume LTIP RSU awards granted over 12,628 shares in total
- Price Nil
h)
Aggregated information
- Aggregated volume
LTIP RSU awards granted over 12,628 shares in total
- Price
Nil
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0)
1865 783 000 / E: cosec@oxb.com (mailto:cosec@oxb.com)
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHBLGDSUBGDGLI
Copyright 2019 Regulatory News Service, all rights reservedRecent news on Oxford BioMedica
See all newsREG - Oxford Biomedica PLC - Grant of Awards
AnnouncementREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - 2026 Annual General Meeting notification
AnnouncementREG - Oxford Biomedica PLC - Preliminary results for the year ended 31 Dec 2025
AnnouncementRCS - Oxford Biomedica PLC - Licensing agreement with VVMF
Announcement